Literature DB >> 6580646

Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.

R F Ebert, W R Bell.   

Abstract

A congenital hypodysfibrinogenemia, fibrinogen Baltimore II, was found in a young asymptomatic Caucasian female. Prothrombin, partial thromboplastin, and euglobulin lysis times were normal, as were platelet function and coagulation factor assays. Subnormal plasma fibrinogen levels were found using chronometric, rate-independent, and immunologic assay methods. Kinetic analysis of fibrinopeptide release revealed a delay in the thrombin-catalyzed release of fibrinopeptide B from the abnormal protein. Proteolysis of fibrinopeptide A by thrombin or Arvin, fibrin monomer polymerization, and fibrin polymer ligation occurred at normal rates. Catabolism of radiolabeled autologous and homologous fibrinogen was also normal, but the fibrinogen synthetic rate was less than half the normal value. Comparison of the coagulation characteristics of fibrinogen Baltimore II with those of other abnormal fibrinogens indicates that it represents a unique example of hypodysfibrinogenemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580646      PMCID: PMC390046          DOI: 10.1073/pnas.80.23.7318

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  PROTHROMBIN: ANALYTICAL AND CLINICAL ASPECTS. COMPARISON OF THE ONE- AND TWO-STAGE METHODS.

Authors:  A J QUICK; C V HUSSEY; M GEPPERT
Journal:  Am J Med Sci       Date:  1963-11       Impact factor: 2.378

2.  A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.

Authors:  R M HARDISTY; J C MACPHERSON
Journal:  Thromb Diath Haemorrh       Date:  1962-05-15

3.  Fibrinopeptide B and aggregation of fibrinogen.

Authors:  J R Shainoff; B N Dardik
Journal:  Science       Date:  1979-04-13       Impact factor: 47.728

4.  Diffusion-in-gel methods for immunological analysis. II.

Authors:  O OUCHTERLONY
Journal:  Prog Allergy       Date:  1962

5.  The partial thromboplastin time as a screening test for the detection of latent bleeders.

Authors:  S W NYE; J B GRAHAM; K M BRINKHOUS
Journal:  Am J Med Sci       Date:  1962-03       Impact factor: 2.378

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue.

Authors:  D L Higgins; J A Shafer
Journal:  J Biol Chem       Date:  1981-12-10       Impact factor: 5.157

8.  Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans.

Authors:  D Collen; G N Tytgat; H Claeys; R Piessens
Journal:  Br J Haematol       Date:  1972-06       Impact factor: 6.998

9.  Fibrinogen Chapel Hill: hypodysfibrinogenemia with a tertiary polymerization defect.

Authors:  R P McDonagh; N A Carrell; H R Roberts; P M Blatt; J McDonagh
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

10.  Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.

Authors:  H R Gralnick; H M Givelber; J R Shainoff; J S Finlayson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

View more
  1 in total

1.  Increased thrombosis susceptibility and altered fibrin formation in STAT5-deficient mice.

Authors:  Sarah M Nordstrom; Brian A Holliday; Brandon C Sos; James W Smyth; Robert E Levy; Jonathan W Dukes; Susan T Lord; Ethan J Weiss
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.